Healthcare reform stopped? Slowed? Dead? Delayed? Yes. (Morning Read)

The next step for the now unconstitutional US healthcare reform efforts (and other Obama setbacks). A doctor who really wasn’t. Boston Scientific’s (long) quest for perfection. Healthcare social media: medical businesses still far away from jumping on board. Plus, Glaxo’s big sports nutrition buy and fresh funding for everything from cancer detection to cardiac surgical devices.

Highlights of the important and interesting in the world of healthcare:

So much for healthcare reform — for now. So a federal judge — a longtime Republican stalwart who may have a substantial stake in an anti-healthcare consulting firm — has said it is unconstitutional to force the uninsured to buy health insurance.

Pick your punditry poison: the decision either has put ObamaCare on the ropes or will have no impact on healthcare reform whatsoever. The administration has said it will continue to enact health reform since the ruling only strikes down the individual mandate due up in 2014. But there are chances now that more states will fight healthcare reform and that the constitutional objections will have more impact on the debate than anyone thought.

But what is now clear is that the challenges from dozens of states to the law’s constitutionality can no longer be dismissed as frivolous, as they were earlier this year by some scholars and Democratic partisans.

“All the insiders thought it was a slam dunk,” said Randy E. Barnett, a professor of constitutional law at Georgetown University who supports the health care challenges. “Maybe a slam dunk like weapons of mass destruction were a slam dunk.”

What do you call the guy who drops out of medical school? A doctor. William Hamman spent nearly two decades training other physicians, sharing in millions in grants and referring to himself as a doctor. He was an airline pilot who attended medical school but never graduated. Here’s the kicker: The American Medical Association — even after learning of the deception — was going to let him lead a seminar and just switch his title from “Dr.” to “Captain” on course materials. Someone higher in the AMA learned of this and canceled his appearance.

Boston Scientific: The perfect stock? Or not. On a perfect stock scale of 1 to 10, Motley Fool gives Boston Scientific a 1: “On the whole, Boston Scientific has a lot of work left to do to turn the corner. Until it does, many of its competitors look a lot more like perfect stocks than Boston Scientific does.”  Was it as lack of perfection — or a quest for it — that caused Boston Scientific to stop seeking a buyer for its pain management unit? Bloomberg said BSX couldn’t agree on the value of the unit.

Life science still shuns social media. Hospitals continue to move full steam ahead with social media. But fear of FDA blowback makes pharma and other life science companies leery of using social media for business: 41 percent of those queried in a Deloitte survey say their company uses online social networks, 21 percent say their companies plan to and 38 percent have no plans to do so.

Pfizer’s loss is Obama’s loss. As if a setback in healthcare reform isn’t enough, it turns out the loss of Pfizer’s chairman and CEO hurts Obama as well:  Jeffrey Kindler, who led the lobbying group PhRMA, was pro-Obama who in four years gave $42,800 in political donations to Democrats and Pfizer’s political action committee. PhRMA’s new leader,Christopher Viehbacher of Sanofi-Aventis, has largely backed Republicans.

Dealflow and more. GlaxoSmithKline makes a move into sports nutrition by buying Maxinitrition Group Holdings for $255 million; Baxter is buying back $2.5 billion in stock; Michigan’s Aastrom Biosciences announces $22.5 million IPO to develop its adult stem cell therapy; Arizona’s WebPT closed a $1 million Series A round for Web-based electronic medical records; Texas’ Ortho Kinematics raised $2 million to develop its spine diagnostics medical device.

Dealsflow and more, Part II. California’s RQx Pharmaceuticals raised $1 million from Avalon Ventures; California’s Estech closed on $8.5 million to continue developing cardiac surgical medical devices; North Carolina’s CeNeRx Pharma closed on a $6 million tranche of the $13 million it raised in August to develop antidepressant drugs; California’s QuantaLife raised $17.2 million to refine gene expression analysis; Michigan’s Armune BioScience wins $500,000 in a business plan competition for its approach to cancer detection.